The US has extended the Priority Review Voucher (PRV) program for rare pediatric diseases.
In February 2026, the United States signed the Consolidated Appropriations Act, 2026, officially extending the Rare Pediatric Disease Priority Review Voucher (PRV) program. The decision enshrines one of the key market mechanisms stimulating the development of drugs for ultra-rare conditions.
The essence of the mechanism
A priority review voucher (PRV) is a regulatory preference granted by the U.S. The Food and Drug Administration (FDA) grants a voucher to a developer when registering a drug for the treatment of a rare pediatric disease (population <200,000 in the US, onset before age 18).
This raises the obvious question: what is the value of a PRV if orphan drugs can already qualify for Priority Review status?
The program has a number of unique characteristics:
- Universality and Liquidity Unlike the standard "breakthrough therapy" designation, the voucher is a transferable asset. It can be used to expedite the approval of any other drug in the company's portfolio (for example, a mass-market blockbuster), reducing the FDA review period from 10-12 months to 6 months.
- Financing Instrument For small biotech companies, selling a voucher to industry giants serves as a way to raise capital without issuing shares. In January 2026, Jazz Pharmaceuticals announced the sale of a voucher for $200 million, confirming the high market value of this asset.
- Time-to-Market (TTM)In a competitive market, a 4-6 month gain allows for earlier monetization of a drug and the capture of market share before competitors emerge.
Program Effect
Since the program's launch in 2012, the FDA has issued more than 80 pediatric vouchers.
Analysis shows:
- More than 90% of drugs approved under this program were the world's first pathogenetic therapies for the corresponding nosologies;
- The program covered 47 unique orphan diseases, including neuromuscular degenerative diseases and rare metabolic disorders.
For physicians and the scientific community, the extension of the PRV signifies continued investment interest in pediatric developments from the industry. Even with a minimal market for an orphan drug, the presence of a voucher makes an R&D project economically feasible due to the high value of the regulatory asset itself.
Read more: https://www.biospace.com/policy/rare-pediatric-disease-vouchers-reauthorized-pbm-reform-funded-in-na...
